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Abstract – 
Cell-free protein synthesis (CFPS) is an in vitro protein synthesis system that provides a uniquely 
adaptable platform for protein production. In recent years, lyophilization of CFPS have expanded the 
capabilities of this system by improving reagent stability outside of cold-chain storage. This project sought 
to utilize lyophilized CFPS reagents to develop a convenient, shelf-stable, on-demand therapeutic protein 
production platform. The therapeutic protein production potential of this novel platform was demonstrated 
by the successful expression of an FDA approved therapeutic protein. With the advancement of shelf-
stable, on-demand protein therapeutic production platforms comes the potential to provide point-of-care 
medical treatment for space-flight crews during long duration missions.
Introduction 
As the dream of long-term space exploration 
becomes a reality, so do the unique health risks 
associated with space flight. Missions requiring 
long-duration habitation beyond low-earth orbit 
pose significant challenges to the health and 
well-being of the crew. Successful medical 
interventions, as well as biomedical 
countermeasures to prevent or mitigate high-risk 
conditions, are contingent on the therapeutics 
available to the crew. Some of the most 
beneficial options for medical care are protein 
therapeutics, as they provide particularly 
effective treatments for cancer, genetic diseases, 
neurological disorders, and radiation syndromes. 
However, the availability of protein therapeutics 
is limited by their low stability under high-levels 
of radiation and long term storage [1].  
This project sought to overcome the challenges 
of protein therapeutic availability during long-
term space flight by engineering a lyophilized 
cell-free protein synthesis (CFPS) system 
capable of producing protein therapeutics on 
demand and with minimal equipment; thus, 
providing life-saving treatments to space flight 
crews.   
Relevance to NASA Aims 
This work focuses on supporting Strategic Goal 
2 of NASA’s 2018 Strategic Plan which is to 
“Extend Human Presence Deeper into Space and 
to the Moon for Sustainable Long-term 
Exploration and Utilization” [2]. In particular, 
this project  addresses the specific challenges 
identified in the NASA Technology Roadmaps: 
pharmaceutical stability under space flight 
conditions (TA 6.3.2), and effective treatment 
options for high-risk medical conditions for long-
duration health (TA 6.5.2) [3]. Potentially, many 
of these challenges can be addressed through on-
demand production of protein therapeutics 
during long-term space flight.  
Protein therapeutic availability on board 
spacecraft can improve treatment options and 
countermeasures during interplanetary missions 
against cancer, genetic diseases, neurological 
disorders, and radiation syndromes (TA 6.5.2.4, 
6.5.2.2, 6.5.2.1). However, the availability of 
these powerful therapeutics during missions is 
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limited by their long-term stability under space-
flight conditions and the difficulty of 
determining the therapeutics one will need prior 
to take-off. On-demand protein therapeutic 
production could eliminate the need to store 
protein therapeutics long-term while also 
improving the versatility of in-flight biomedical 
countermeasures and treatments 
Background 
Cell-free Protein Synthesis 
The production of proteins requires biological 
processes as conducted by specialized cellular 
machinery. The traditional method of protein 
manufacturing produces proteins within living 
cell cultures, or in vivo. These cell-based 
production platforms are dependent on the 
growth and replication of living cells and 
therefore require time intensive production, 
purification, and protein isolation steps. Protein 
therapeutics are conventionally purified and 
stored in aqueous or dried form in low 
temperature storage until administration. 
However, stability of these isolated proteins is 
limited over time with elevated temperatures.  In 
vitro cell-free protein synthesis systems (CFPS) 
are an emerging production platform that provide 
an alternative approach to conventional protein 
production and storage. CFPS platforms 
circumvent many of the disadvantages of in vivo 
manufacturing and present the capability of on-
demand protein therapeutic production. 
 On-demand protein therapeutic production 
through CFPS may enable spaceflight crews to 
produce protein therapeutics as the need arises as 
opposed to relying on spacecraft inventory which 
may be limited by payload restrictions and 
therapeutic stability limitations. Protein 
therapeutics are most commonly expressed in 
vivo; however, cellular systems are not 
particularly effective in the space environment 
due to cell destruction under ionizing radiation 
[4]. These in vivo systems also require a 
significant amount of equipment and complex 
purification steps. Alternatively, CFPS systems 
make it possible to synthesize proteins outside of 
a cell by combining the DNA of the protein of 
interest with emancipated cellular machinery in a 
reaction vessel (Figure 1). Cell-free expression 
has been demonstrated on a wide array of 
therapeutic proteins including antibodies, 
vaccines, and cancer drugs [5]. CFPS technology 
facilitates rapid product purification with 
minimal equipment and provides an efficient 
protein production platform with high protein 
yields in as little as an hour which is an order of 
magnitude faster than in vivo production [6]. 
 Lyophilization  
CFPS provides rapid recombinant protein 
production; however, the major components of a 
cell free system must be stored in aqueous 
solutions below freezing [7]. To ensure protein 
synthesis viability, the CFPS solutions are most 
Figure 1: Illustration of CFPS: E. Coli cells are lysed for components to be used in a CFPS system for the 
production of protein therapeutics or other biocatalysts. 
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commonly maintained at -80°C, requiring low 
temperature freezers. To overcome this 
drawback, lyophilization can be used to preserve 
CFPS systems. Lyophilization, or freeze-drying, 
is a commonly used preservation technique on 
consumables to extend shelf-life, reduce volume 
and weight, and lower bacterial contamination. 
We can utilize this technique on CFPS systems 
with minimal disruption in efficacy as they do not 
require living cells. A CFPS system can therefore 
be created from lyophilized, shelf-stable reagents 
(Figure 4) [8]. These ready-made powdered 
CFPS systems are capable of high-density, 
thermostable storage with the proven capacity to 
produce protein therapeutics [9]. An example of 
a stored, small-scale lyophilized CFPS system is 
shown in Figure 2.  
Figure 2: Image of Lyophilized CFPS system stored in 
test tube 6 months at room temperature 
Initial lyophilization work using freeze-dried cell 
extracts and separate powdered energy systems 
demonstrated that the lyophilized systems retain 
viability over a 60-day period at room 
temperatures [8] and in follow on work has 
demonstrated retained activity after 1 year when 
stored at 4°C. In comparison, all activity was lost 
in the non-lyophilized sample [9]. Additionally, 
cryoprotectant additives can be considered for 
even greater retention of CFPS activity over 
longer storage periods. Initial studies using 
cryoprotectant have shown promise for 
prolonged storage [10].  
Previous iterations of lyophilized CFPS have 
required the cell extract and energy mix to be 
stored separately. One reason for this may be the 
hydrophobic nature of some of the components 
of the energy mix which may decrease its dry 
storage capacity. However, separate storage of 
the cell extract and energy mix limits the 
convenience of the current lyophilized CFPS 
systems. A one-pot CFPS platform which only 
requires rehydration of water and addition of 
DNA template would provide a straightforward, 
user-friendly platform. To this aim, this project 
sought to optimize lyophilization and 
cryoprotectant additives to enhance preservation 
of a one-pot CFPS system.  
Convenient Downstream Purification  
One of the most significant challenges to on-site, 
point-of-care production is purification 
efficiency and the risk of endotoxin exposure 
from incomplete purification of bacteria residue. 
Commercial protein therapeutic production relies 
on extensive purification and quality control 
steps to ensure complete endotoxin removal. 
These steps require a high degree of specialized 
equipment and personnel training.  However, an 
on-demand, point-of-care production platform 
should be able to produce and purify a protein 
therapeutic with minimal equipment and 
training.  To address this challenge, our lab 
recently developed an “endotoxin-free” CFPS 
system using a commercial LPS-free cell strain 
ClearColi™BL21(DE3) [9]. By eliminating the 
source of toxic LPS the risk of endotoxin 
exposure during therapeutic administration is 
essentially eliminated.  
We have demonstrated the use of ClearColi™ in 
conventional CFPS systems [11] as well as our 
lyophilized on-demand CFPS system [12]; 
however, the preparation of ClearColi™ extract 
required in the CFPS systems remains time-
consuming and labor-intensive because of the 
relatively slow growth kinetics of the 
ClearColi™ cell strain. This project sought to 
develop an improved protocol for the preparation 
of ClearColi™ cell extract for CFPS systems. 
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Here we report a streamlined procedure for 
preparing ClearColi™ cell extract using an auto-
induction media (AIM). AIM is an engineered 
cell culture media which achieves protein 
expression by catabolite repression of the 
lacUV5 promoter and eliminates the need for 
manual induction of protein expression. 
Culturing Clearcoli™ cells in autoinduction 
media significantly reduces the hands-on time 
required during extract preparation and has 
demonstrated improved extract efficacy. 
Experimental Methods 
CFPS Reactions 
CFPS reactions were formulated with 25 vol 
percent cell extract, 25 vol percent PANOxSP 
energy mix as previously described [13], 12 nM 
plasmid DNA, and ultrapure water to volume. 
Reaction was incubated 3 h at 37 °C and 120 rpm. 
Production yields of super-folder green 
fluorescent protein (sfGFP) were determined by 
fluorescence at 485/510 excitation/emission 
wavelengths according to a standard curve 
created by C14-leucine labeled proteins, as 
reported previously [7]. Crisantaspase was 
expressed for 6.5–8 h at 30 °C and 120 RPM and 
yield was determined using C14 labeled leucine 
as previously described [7]. 
Cell Extract Preparation and Lyophilization  
Cell-free extracts were prepared from 
ClearColi™ BL21 (DE3) strains as described 
previously [2]. Briefly, cells were grown in 2.5 L 
Tunair flasks (IBI Scientific, Peosta, IA) and 
production of T7 RNA polymerase was induced 
via addition of 1mM IPTG during early 
exponential growth. Cells were harvested in mid 
log phase by centrifugation at 6000 rcf for 10 
min. Cells were homogenized at 21,000 psig in 
an Avestin French Press. Prior to lyophilization, 
cryoprotectants were added to cell extract 
samples as specified in Table 1 [12]. 
Additionally, the energy system PANOxSP[13] 
was added to the samples prior to lyophilization. 
Samples were frozen in a -40°C ethanol bath 
(Just-A-Tilt Shell Freezer Chiller SF-4Az, FTS 
Systems, Warminster, PA). Samples were then 
lyophilized (Flexidry MP, FTS Systems). After 
approximately 1.5 hours of freeze-drying, 
samples reached minimum weight suggesting 
samples were sufficiently dried. 
Lyophilized CFPS systems were stored at 4°C, 
25°C, 37°C, and 50°C for 90 days and tested 
periodically for protein synthesis activity. 
Activity was determined by measuring 
production yields of sfGFP.  To demonstrate the 
capacity of this system to produce protein 
therapeutics, the FDA approved cancer 
therapeutic crisantaspase was also produced after 
46 days of storage.  
Streamlined Endotoxin-free CFPS 
Preparation  
AIM induction kinetics were investigated to 
determine optimal cell culture fermentation.  
Auto-induction media was adapted from the 
“ZYM-5052” protocol reported by Studier [29]. 
1 mL overnight culture of BL21 Star™(DE3), 
and BL21 Star™(DE3)-pY71-sfGFP were was 
added to 100 mL AIM with either 0.05 or 1% w/v 
final glucose concentrations. Cultures were 
fermented at 37°C and 280 rpm. Absorbance 
(OD600) of cultures were read 2 or 3 times per 
hour for 12 h. Simultaneously, fluorescence of 
100 μl of cell culture were measured with 
Synergy-MX Multi-Plate Reader (Biotek, 
Winooski, VT). ClearColi™ BL21(DE3) growth 
and induction kinetics were assessed similarly 
Table 1  
Cryoprotectant content and concentrations [12] 
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except OD600 and culture fluorescence were 
measured once per hour for 15 h. 
After AIM induction kinetics were elucidated, 
the efficacy of cell extract produced by AIM was 
tested.  ClearColi™ was fermented in 1.5 L AIM 
prepared to 0.05% final glucose concentration in 
2.5 L Tunair shake flasks. Cultures were 
fermented at 37 °C and 280 rpm. ClearColi™ cell 
culture was harvested at 5.4 h (OD600 = 1.0), 7.7 
h (OD600 = 3), and 9.8 h (OD600 = 7.0) of 
fermentation. Cells were homogenized as 
described above.  As with the lyophilized extract, 
AIM prepared ClearColi™ extract was tested by 
measuring production levels of sfGFP protein. 
Similarly, to demonstrate the capacity of this 
system to produce protein therapeutics, the FDA 
approved therapeutic crisantaspase was 
produced. 
Results 
This project advanced on-demand CFPS systems 
capable of producing yields appropriate for 
therapeutic doses. We have achieved an 
improved lyophilized, endotoxin-free CFPS 
system from those previously reported by our lab 
and others. For on-demand CFPS protein 
production, this new system only requires 
rehydration with water and the addition of the 
DNA template of choice. Additionally, the 
preparation of the endotoxin-free cell extract was 
optimized for improved preparation efficiency 
and extract efficacy.  
The lyophilized, on-demand CFPS system held 
activity after storage at elevated temperatures. 
Samples containing cryoprotectants showed 
prolonged activity over that of the control system 
as presented in Figure 3A. The potential of using 
these lyophilized CFPS systems for protein 
therapeutic production was demonstrated by the 
production of the FDA-approved cancer 
therapeutic crisantaspase. Active crisantaspase 
was produced at significant yields after 46 days 
of storage at elevated temperatures (Figure 3B). 
The promising results of our novel lyophilized 
on-demand CFPS system demonstrated a viable 
shelf-stable, one-pot CFPS system utilizing 
endotoxin-free ClearColi™ cell extract.  
The promising results from this study prompted 
further research into optimizing the preparation 
of the ClearColi™ cell extract. We demonstrated 
a streamlined procedure for preparing 
ClearColi™ cell extract using AIM. This new 
protocol still requires a greater amount of time 
than that of traditional BL21 Star (DE3) as shown 
by the growth kinetics in Figure 4A; however, it 
significantly reduces required hands-on time. In 
Figure 3: A) sfGFP yields after storage at 4°C, 25°C, 37°C, and 50°C from CFPS systems lyophilized with and without 
cryoprotectants. Sample combinations are described in Table 1. Extract only sample was not lyophilized with PANOxSP; B) 
Crisantaspase yields from CFPS system lyophilized with Dextran cryoprotectant after 46 days of storage.  
B A 
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particular, AIM reduces the need to monitor the 
cells throughout growth and eliminates manual 
induction. We report that the optimal time to 
harvest ClearColi™ to obtain cell extract for 
high-yielding CFPS is at early to mid-log phase 
which equates to ~5.5-8 h after initial cell 
inoculation. Even waiting 10 h after initial cell 
inoculation still resulted in decent protein 
expression yields in CFPS (See Figure 4B for 
protein expression yields at different harvest 
times). These results suggest that not only does 
AIM simplify preparation procedures but also 
allows for more flexibility in the timing of 
harvest.  
The performance of ClearColi™ cell extracts 
prepared by AIM were further tested by 
producing the protein therapeutic crisantaspase. 
AIM prepared ClearColi™ proved to maintain 
the same cell-free protein synthesis capability as 
extract produced with traditional fermentation 
and induction methods as demonstrated by the 
high-yield expression of crisantaspase as shown 
Figure 4C. These results suggest that preparing 
ClearColi™ cell extract with AIM is superior to 
that of traditional preparation methods as it is 
significantly more efficient while still 
maintaining equivalent-yielding CFPS.  
A full disclosure and extended discussion of the 
experimental methods and results of this project 
are documented in the articles: 1)  “Thermostable 
lyoprotectant-enhanced cell-free protein 
synthesis for on-demand endotoxin-free 
therapeutic production” (New BioTechnology), 
and  2) “Streamlining the preparation of 
‘endotoxin-free’ ClearColi cell extract with 
autoinduction media for cell-free protein 
synthesis of the therapeutic protein 
crisantaspase” (Synthetic and Systems 
Biotechnology).  
Conclusion  
Lyophilization, of cell-free systems creates rapid 
protein synthesis systems that can be created in 
mass and stored for later use on an on-demand 
basis. This ready-made powdered CFPS provides 
high density and non-standard temperature 
storage improving the overall cost, 
transportability, and convenience of a CFPS 
system. Additionally, this unique CFPS system 
utilizes an endotoxin-free cell extract which 
eliminates costly and time-consuming 
purification steps.  
This work constitutes an important study for the 
design of lyophilized CFPS systems for 
prolonged storage by demonstrating the robust 
nature and therapeutic production capacity of an 
on-demand protein production platform. 
Significant progress has been made towards the 
development of practical on-demand CFPS 
Figure 4: A) Kinetic growth curves (OD600) and harvest 
times of BL21 Star™(DE3) and ClearColi™ cells 
prepared in AIM; B) CFPS sfGFP expression yield from 
ClearColi™ cell extract prepared using AIM as 
compared to sfGFP yield from ClearColi™ cell extract 
prepared using traditional fermentation and induction 
method; C) Crisantaspase yields using ClearColi™ cell 
extract prepared with AIM compared to yields using 
traditional fermentation and induction methods.  
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systems for therapeutic protein production during 
long-term space flight. The advancements made 
through this project are particularly important in 
streamlining the production of protein therapetics 
outside of commercial centralized facilities. In 
particular, we have simplified the fermentation 
process of the cell extract, improved CFPS long-
term storage, and eliminated endotoxin removal 
steps. Figure 4 summarizes these advancements.  
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Figure 4: Steps associated with protein therapeutic production through commercial manufacturing (top) and the novel CFPS on-
demand , endotoxin-free system described in this work (bottom). 
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